NCT00351468 · OUTCOME

Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.

EXTEND (Eltrombopag Extended Dosing Study) · Source last updated 2017-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline up to 2 years

What was measured

Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.

Groups in this outcome

Eltrombopag

Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Eltrombopag	302

Reported measurements

ITP medication at baseline

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Eltrombopag	101	Not reported	Not reported	Not reported	Not reported

Sustain reduct or stop at least 1 med [1] n=101

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Eltrombopag	71	Not reported	Not reported	Not reported	Not reported

Permanently stopping at least 1 ITP med [1] n=101

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Eltrombopag	53	Not reported	Not reported	Not reported	Not reported

Sustained reduction[1] n=101

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Eltrombopag	70	Not reported	Not reported	Not reported	Not reported

Maximum sustained reduction ≥ 24 weeks[2] n=70

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Eltrombopag	66	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
101
title
ITP medication at baseline
categories
measurements
group Id
OG000
value
71
title
Sustain reduct or stop at least 1 med [1] n=101
categories
measurements
group Id
OG000
value
53
title
Permanently stopping at least 1 ITP med [1] n=101
categories
measurements
group Id
OG000
value
70
title
Sustained reduction[1] n=101
categories
measurements
group Id
OG000
value
66
title
Maximum sustained reduction ≥ 24 weeks[2] n=70

denoms

counts
group Id
OG000
value
302
units
Participants

description

groups

description
Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.
id
OG000
title
Eltrombopag

param Type

NUMBER

reporting Status

POSTED

time Frame

Baseline up to 2 years

title

Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice